Table 3

Cox proportional HR for the risk of hospitalised HF in TNF antagonist users compared with nbDMARDs

AnalysisHF HR (95% CI) (as treated)HF HR (95% CI) (first exposure carried forward)
Any HF, total population0.84 (0.62 to 1.12)0.89 (0.69 to 1.15)
Known HF*0.95 (0.58 to 1.57)0.94 (0.62 to 1.43)
No known HF0.86 (0.58 to 1.27)0.94 (0.70 to 1.33)
  • *Known HF was defined as persons with an acute care hospitalisation for HF during the 365 day baseline period prior to the start of follow-up. All models used the propensity score trimmed cohorts and included the 180-day prior cumulative oral glucocorticoid dosage, the number of HF hospitalisations and the use of  loop diuretics.

  • nbDMARD, non-biological disease modifying antirheumatic drug; HF, heart failure